Advances in Chemotherapy of Non-small Cell Lung Cancer

Learning Objectives: Significant improvements in median survival and 1 and 2-year survival rates in patients with lung cancer are due in part to the use of platinum-based regimens with newer chemotherapy agents and targeted therapy, including the vascular endothelial growth factor (VEGF) inhibitor bevacizumab. New agents such as monoclonal antibodies, small molecule inhibitors of tyrosine kinase, and direct inhibitors of proteins involved in lung cancer proliferation are being developed and may improve outcomes in patients with lung cancer.